Ace inhibitor study for early Alport syndrome
Treatments studied
Part of Genetic & congenital, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a medicine called an ACE inhibitor (a type of blood pressure drug) in people with early-stage Alport syndrome, a genetic kidney condition. The goal is to see if it can protect kidney function and reduce protein in urine, before kidney damage gets worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Alport syndrome and have blood in your urine.
- Your kidney function is still normal or close to normal (eGFR greater than 90).
- You may have small amounts of protein in your urine, but not too much.
- You are between 30 and 50 years old.
- You are not currently taking any ACE inhibitor or similar blood pressure medications.
- You do not have other kidney diseases, low blood pressure, or high potassium levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how specific genetic changes (genotypes) relate to kidney problems and urine blood findings in people with Alport syndrome. It may help doctors predict disease course and tailor care, though it may not involve new treatment.
This is a registry that collects information from people with Alport syndrome to better understand the disease and how to delay kidney failure. It may help researchers learn which factors and treatments are most important over time.
This study follows people diagnosed with Alport syndrome to better understand the condition and its effects. It may help researchers learn what to watch for over time and how the disease progresses.
This registry collects health information from people with Alport syndrome to help researchers better understand the condition and improve future treatments.
This study tests if stem cells from umbilical cord blood can help children aged 3 to 12 with Alport syndrome, a genetic kidney disease. It aims to slow kidney damage and improve function.
This trial tests a new medicine (sitogilun malate) combined with a standard blood pressure drug (amlodipine) to see if it protects the kidneys in people with early kidney damage caused by high blood pressure. Participation could help prevent further kidney damage while controlling your blood pressure.
Hear when a new Alport Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.